2026-10-13T14:50:38Z https://api.figshare.com/v2/oai

oai:figshare.com:article/32632482 2026-10-01T17:11:10Z portal_1172 item_type_8 month_year_10_2026

Exacerbation and glucocorticoid toxicity profile in patients receiving mepolizumab for severe eosinophilic asthma Pamela Jane McDowell (13406403) PUREID: 297759532 Asthma eosinophilic T2 high monoclonal antibodies The treatment of patients with severe eosinophilic asthma has been transformed with the arrival of biological drugs targeting the type 2 cytokine pathway. One of these drugs is mepolizumab, a humanised monoclonal antibody against the eosinophil activating cytokine, interleukin (IL)-5, has consistently been shown to lead to a 50% reduction in exacerbation rate, when compared with placebo, and facilitates the weaning of maintenance oral corticosteroids (OCS) in patients with severe eosinophilic asthma. <br><br>This works seeks to address two questions that arise from treatment with this novel monoclonal antibody:<br><br>1. What is the inflammatory phenotype and the physiological characteristics of the residual asthma exacerbations that occur in patients with severe eosinophilic asthma treated with anti-IL5 monoclonal antibodies?<br><br>2. To quantify toxicity associated with OCS treatment in severe eosinophilic asthmatics, and assess change in OCS-related toxicity after 1 year's treatment with mepolizumab and subsequent reduction in OCS, both through weaning of maintenance OCS and reduction in OCS for asthma exacerbations. 2026-10-01T17:11:10Z Text Thesis 10.17034/32632482.v1 https://figshare.com/articles/thesis/Exacerbation_and_glucocorticoid_toxicity_profile_in_patients_receiving_mepolizumab_for_severe_eosinophilic_asthma/32632482 All Rights Reserved